(Q30940476)

27 June 2017

title

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial (English)

1 reference

27 June 2017

author

Elizabeth Barrett-Connor

1

object named as

Elizabeth Barrett-Connor

0 references

Jane A. Cauley

object named as

Jane A Cauley

2

0 references

Andreas Sashegyi

4

object named as

Andreas Sashegyi

1 reference

27 June 2017

6

Mary Jane Geiger

1 reference

27 June 2017

Pandurang M Kulkarni

3

1 reference

27 June 2017

David A Cox

5

1 reference

27 June 2017

publication date

12 April 2004

1 reference

Journal of Bone and Mineral Research

27 June 2017

published in

1 reference

27 June 2017

volume

19

1 reference

27 June 2017

issue

8

1 reference

27 June 2017

page(s)

1270-1275

1 reference

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Estrogen plus progestin and the risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Postmenopausal hormone replacement therapy: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Serum estradiol level and risk of breast cancer during treatment with raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Effects of estrogen plus progestin on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Design and methods of the Raloxifene Use for The Heart (RUTH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. World Health Organization Collaborative Study of Cardiovascular and Steroid Hormone Contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Low Bone Mineral Density in the Hip as a Marker of Advanced Atherosclerosis in Elderly Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040406

21 January 2018

Identifiers

DOI

10.1359/JBMR.040406

1 reference

27 June 2017

1 reference